Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harvey Maksvytis

Internal Medicine Tucson, AZ Medical Doctor

NPI 1770550220 CMS profile 79951

1 W Broadway Blvd Ste 151, Tucson, AZ 85701

Open in the dashboard

General payments

$3,862

256 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harvey Maksvytis of Tucson, AZ is reported in the CMS Open Payments database as having received $3,862 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $62 1
2023 General $210 4
2021 General $554 33
2020 General $699 43
2019 General $2,337 175

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harvey Maksvytis
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Harvey Maksvytis were reported at $62. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Harvey Maksvytis Internal Medicine median Middle half National median
2019 $2,337 $159 $48–$570 $163
2020 $699 $119 $33–$402 $114
2021 $554 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $210 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $62 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $670 41 payments
  2. Janssen Pharmaceuticals, Inc $485 32 payments
  3. AstraZeneca Pharmaceuticals LP $354 7 payments
  4. Novartis Pharmaceuticals Corporation $296 34 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $280 28 payments
  6. Novo Nordisk Inc $193 26 payments
  7. Sanofi-Aventis U.S. LLC $162 12 payments
  8. Sunovion Pharmaceuticals Inc. $139 10 payments
  9. Alkermes, Inc. $128 7 payments
  10. Averitas Pharma Inc. $122 1 payment
  11. Other $1,032 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,856 255 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $555 35 payments
  2. XARELTO $395 28 payments
  3. ENTRESTO $296 34 payments
  4. Otezla $167 8 payments
  5. Ozempic $141 18 payments
  6. Qutenza $122 1 payment
  7. WATCHMAN $121 7 payments
  8. remede System $118 1 payment
  9. ARISTADA INITIO $111 6 payments
  10. ARISTADA $111 6 payments
  11. Other $2,833 204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

3,385

Median for Internal Medicine: 777

Drug cost

$343,296

Median for Internal Medicine: $73,373

Branded share of claims

21.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 82 $72,890
Repatha Sureclick Evolocumab Brand 67 $68,658
Eliquis Apixaban Brand 53 $44,861
Ozempic Semaglutide Brand 21 $36,723
Prolia Denosumab Brand 11 $18,678
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $14,731
Spiriva Respimat Tiotropium Bromide Brand 17 $13,252
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 22 $7,041
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 15 $6,646
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 26 $5,756

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$10,089

Of which drugs: $4,879

Medicare patients

88

Average age 76

Services billed

414

43 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 44%
Ischemic heart disease 33%
Diabetes 30%
Cancer 22%
Depression 19%
Osteoporosis 18%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 23 26 $2,068

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record